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Abstract
Background: Using next-generation sequencing (NGS) in newborn screening (NBS) could expand the number of
genetic conditions detected pre-symptomatically, simultaneously challenging current precedents, raising ethical
concerns, and extending the role of parental decision-making in NBS. The NC NEXUS (Newborn Exome Sequencing
for Universal Screening) study seeks to assess the technical possibilities and limitations of NGS-NBS, devise and
evaluate a framework to convey various types of genetic information, and develop best practices for incorporating
NGS-NBS into clinical care. The study is enrolling both a healthy cohort and a cohort diagnosed with known
disorders identified through recent routine NBS. It uses a novel age-based metric to categorize a priori the large
amount of data generated by NGS-NBS and interactive online decision aids to guide parental decision-making.
Primary outcomes include: (1) assessment of NGS-NBS sensitivity, (2) decision regret, and (3) parental decision-making
about NGS-NBS, and, for parents randomized to have the option of requesting them, additional findings (diagnosed
and healthy cohorts). Secondary outcomes assess parents’ reactions to the study and to decision-making.
Methods/design: Participants are parents and children in a well-child cohort recruited from a prenatal clinic and a
diagnosed cohort recruited from pediatric clinics that treat children with disorders diagnosed through traditional NBS
(goal of 200 children in each cohort). In phase 1, all parent participants use an online decision aid to decide whether to
accept NGS-NBS for their child and provide consent for NGS-NBS. In phase 2, parents who consent to NGS-NBS are
randomized to a decision arm or control arm (2:1 allocation) and learn their child’s NGS-NBS results, which include
conditions from standard (non-NGS) NBS plus other highly actionable childhood-onset conditions. Parents in the
decision arm use a second decision aid to make decisions about additional results from their child’s sequencing. In
phase 3, decision arm participants learn additional results they have requested. Online questionnaires are administered
at up to five time points.
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Discussion: NC NEXUS will use a rigorous interdisciplinary approach designed to collect rich data to inform policy,
practice, and future research.
Trial registration: clinicaltrials.gov, NCT02826694. Registered on 11 July, 2016.
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Background
Universal newborn screening (NBS) is a highly successful
public health program through which early detection and
effective intervention result in documented benefits. Most
countries have established criteria for which disorders to
include in NBS. The United States, for example, is guided
by the Recommended Uniform Screening Panel (RUSP), a
list of conditions that meet strict evidence-based standards
for demonstrated benefits [1]. More variability is evident in
the secondary conditions that are reported, for disorders
that do not meet the primary criteria for screening but
nonetheless are detected [1, 2]. Advances in technology,
such as next-generation sequencing (NGS), could greatly
expand the number of conditions detected by NBS. The
potential benefits of expansion are, however, tempered by
the much slower rate of the development of effective treat-
ments for the large number of conditions that could poten-
tially be identified. The gap between enhanced diagnostic
ability and the lack of effective treatments means that
many identified conditions would not meet the standard
criteria for inclusion in NBS. In addition, screening
healthy newborns using NGS will create novel and pro-
found implementation challenges and pose significant
ethical considerations that may conflict with current
policies governing the role of parental consent for test-
ing. A rigorous scientific and ethical examination of the
utility, acceptability, and consequences of using NGS
for NBS is essential before widespread implementation
can be considered [3–8].
Current applications of NGS targeted to newborns and
children include its use in the diagnosis of critically ill
infants with suspected genetic disorders [1, 6, 9–11];
however, it is the potential application of NGS to screen
healthy newborns that creates novel challenges. The U.S.
Department of Health and Human Services Secretary’s
Advisory Committee on Heritable Disorders in Newborns
and Children conducts a rigorous condition-by-condition
review as the basis for RUSP [2]. The introduction of NGS
as a screening modality would alter the current assessment
of the risks and benefits of NBS because it can identify
conditions for which early identification and treatment do
not confer strictly defined medical benefits as well as those
conditions that lack any established medical treatments
[12, 13]. As a result, there is great interest in considering
how meaningful parental informed consent about a range
of conditions for which their newborn could be tested
might be incorporated into NBS—a change that will re-
quire a deeper understanding of how parents might make
these decisions [14–17].
The introduction of NGS to NBS would also chal-
lenge the precedent of confining NBS to detecting
childhood-onset conditions that require effective treat-
ment to be initiated soon after diagnosis [2, 3, 7].
Currently, the onset of symptoms of some NBS condi-
tions, such as medium chain acylCoA-dehydrogenase
deficiency (MCADD), may be delayed into adulthood
due to variable expressivity; however, NGS could delib-
erately target adult-onset conditions, evoking important
questions about which age standards are appropriate
for an NBS policy. Likewise, the universal disclosure of
carrier status for recessive conditions, which usually
have few or no immediate health implications for the
individual but may inform later reproductive decisions,
would conflict with current ethical guidelines regarding
pediatric genetic testing [3, 18] and (since most individ-
uals will have several findings indicating carrier status)
effectively turn the public health NBS program into a
massive carrier screening program.
Some advocates have urged that the concept of direct
benefits is expanded to include other relatives, such as
parents, since in many cases of dominant adult-onset
conditions, the parents could unknowingly have the
same pathogenic variant as their child, thus potentially
shortening their lifespan and subsequently impacting the
child’s well-being [6, 19]. In such cases, parents would
be making a decision about learning results that could
directly benefit themselves at the cost of negating the
child’s capacity to make this decision in the future.
Perhaps equally contentious is the possibility that
genomic sequencing could identify variants that predict
a childhood-onset condition for which little or no effect-
ive treatment currently exists. As a result, defining the
criteria for determining which information should be
sought and disclosed to parents could be one of the
thorniest implementation challenges facing clinicians
and policy makers. Asking parents to make decisions
about the types of NBS results they wish to learn would
fundamentally alter the role parents have traditionally
played in this setting and would create an urgent need
to develop effective decision-support tools.
The NC NEXUS (North Carolina Newborn Exome
Sequencing for Universal Screening) study is designed to
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address some of these issues by evaluating how the use
of NGS can extend the utility of current NBS. One
important feature of the study is that it recruits two
cohorts of children: one cohort with a condition recently
diagnosed through standard NBS and one cohort of
newborns identified during a healthy pregnancy (see
below). Recruiting diagnosed children enables a novel
evaluation of the sensitivity of NGS-NBS, ascertained by
comparing NGS-NBS results to genes associated with
the diagnosed children’s underlying condition (diagnosed
cohort only). A second important feature of the study is
an embedded two-arm parallel-group randomized con-
trol trial. After learning their child’s NGS-NBS results,
families will be randomized either to have or not to have
the choice to learn additional findings from their child’s
sequencing. This study design will allow us to investigate
differences in decision regret in the two arms of the
study, which is the second primary outcome of the
study. The third primary outcome is parents’ decisions
about NGS-NBS and, for those randomized to be able to
learn them, additional findings. We will also investigate
secondary outcomes that assess parents’ reactions to the
study and to decision-making. This paper summarizes
the NC NEXUS protocol, which is designed to achieve
the foregoing aims.
Methods/design
Study design overview
NC NEXUS is one of four projects run by the Newborn
Sequencing in Genomic Medicine and Public Health
(NSIGHT) consortium, jointly funded by the Eunice
Kennedy Shriver National Institute for Child Health and
Human Development and the National Human Genome
Research Institute. These studies explore, in a limited
but deliberate manner, the implications, challenges, and
opportunities associated with the possible use of gen-
omic sequence information in the newborn period [11].
Each NSIGHT project acquires and analyzes genomic
datasets that considerably expand the scale of data
that has historically been available for analysis in the
newborn period.
The NC NEXUS project studies parental decision-making
about accepting genomic information about medically
actionable disorders of childhood for their child or infant
using a tiered informed consent process and a two-arm
parallel-group randomized controlled trial conducted in a
large U.S. academic medical center (Additional file 1). In
addition, after learning those results, parents who are
randomized to a decision arm are asked whether they wish
to learn additional genomic information that is classified
according to the degree of clinical actionability and age of
onset or the age at which intervention would be initiated.
The study examines the efficacy of an interactive, web-based
decision aid intended to support parental informed
decision-making by providing education about genomic se-
quencing and the kinds of conditions that could be identi-
fied. The decision aid is designed to help parents explore the
degree to which having NGS-NBS is either congruent or in
conflict with their values and preferences and precedes an
in-person consent visit by a genetic counselor [20]. Parents
randomized to the decision arm also view a second
web-based decision aid designed to support informed
decision-making about three categories of additional infor-
mation they can learn from their child’s or infant’s genome.
Questionnaires gather data to evaluate correlates and pro-
cesses of parents’ decision-making and their decision out-
comes, as well as the psychosocial impact of screening.
Additional analyses will explore moderators of effects of
learning about and being able to request additional informa-
tion from an infant’s or child’s sequencing, secondary out-
comes, and couples’ decision processes. The study consists
of three phases, which are summarized in the study design
workflow (Fig. 1) and the SPIRIT figure (Fig. 2).
Eligible participants and recruitment
Participants can be either sex and of any race or ethnicity
and must be fluent in English or Spanish. Parents and their
eligible child are enrolled from two cohorts: the well-child
cohort or the diagnosed cohort. The well-child cohort is
recruited prenatally and consists of parents with a normal
intrauterine pregnancy of 18 weeks or greater with no
pending or positive prenatal diagnostic test results for
congenital malformations or chromosomal abnormalities
(see Table 1 for additional inclusion and exclusion criteria).
The diagnosed cohort consists of parents and children up
to age 5 who have disorders identified through current
NBS in North Carolina. These include metabolic disorders
(such as phenylketonuria and MCADD), cystic fibrosis,
CFTR-related metabolic syndrome, congenital hearing loss,
primary ciliary dyskinesia, and other rare conditions
(including some that have been recommended for in-
clusion on the NBS panel, but for which no screening
method exists).
Due to the assessment by the institutional review board
(IRB) at the University of North Carolina at Chapel Hill
(UNC) that the study poses more than minimal risk to the
child, both members of a couple are required to provide
signed informed consent for testing. Therefore, both are
recruited to the study except if fathers are determined not
to be reasonably available [21]. In those cases, mothers are
eligible to participate independently. Otherwise, both
parents are expected to attend the consent visit. One
parent can consent by telephone in the rare cases
where it is not possible for both parents to attend.
Potential participants in the well-child cohort are
recruited in-person during a regularly scheduled visit at
the obstetrics clinic at UNC Hospitals. Interested cou-
ples who agree to hear about the study are given a
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Fig. 1 (See legend on next page.)
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brochure and an information sheet that describes study
activities. Parents in the diagnosed cohort are recruited
by a letter from their child’s clinician and are also sent
the brochure, the information sheet, and an opt-out
card. If parents in either cohort consent to join phase 1
of the study, they will complete an online baseline ques-
tionnaire (time 1) and use an online decision aid that
will help them decide whether to accept NGS-NBS for
their child. If they prefer, parents can complete a paper
version of the time 1 questionnaire while they are waiting
for their appointment. Parents who do not complete the
time 1 questionnaire within 2 weeks are mailed a paper
version, along with an addressed stamped envelope.
During the initial stage of the study, an age-based
semi-quantitative metric was developed based on previ-
ous work by this research group [22]. This metric was
used to score and categorize the different types of poten-
tial genomic findings to guide informed decision-making
and the disclosure of results. In addition to consider-
ations of the age of disease onset, the metric uses the
concept of medical actionability, which includes the
likelihood and severity of disease outcomes and the
efficacy and potential harms of interventions. The metric
was used to score gene–disease pairs to determine their
eligibility to be included in a NGS-NBS panel that
includes genes associated with disorders that are cur-
rently in the RUSP as well as other conditions with onset
in infancy or childhood that have treatment, monitoring,
or medical management that can be reasonably expected
to improve outcomes (are medically actionable). Because
the conditions identified by the NGS-NBS panel are
comparable to those detected by current NBS screening,
the results of the analyses of these genes are disclosed to
all study participants.
Categories of genomic information
Conditions that did not meet eligibility for the NGS-NBS
panel include those that scored low on the medical action-
ability criteria or had onset in adulthood. Parents random-
ized to the decision arm are eligible to request variant
analysis in three additional categories: (1) adult-onset
conditions with high medical actionability scores, in which
the onset or initiation of screening protocols occurs after
age 18, such as hereditary breast and ovarian cancer; (2)
childhood-onset conditions that have no specific medical
interventions and thus, scored low on medical actionabil-
ity, such as Tay–Sachs disease; and (3) carrier status for
autosomal recessive disorders, such as cystic fibrosis, that
have reproductive, but rarely personal health implications.
Variants associated with adult-onset conditions that
scored low on medical actionability, such as amyotrophic
lateral sclerosis, are neither analyzed nor offered as a
choice for parents.
Sequencing methods
Duplicate saliva samples from the children and infants
are collected and labeled with study ID numbers. Raw
sequence data are analyzed using standard bioinformat-
ics methods to map sequence fragments and align them
to the reference human genome. Genetic variants are
identified using a custom pipeline, deposited in a dedi-
cated database, and extensively annotated and subjected
to in silico analysis [23, 24]. Clinical interpretation of the
variants follows criteria established by the American
College of Medical Genetics and Genomics [25]. How-
ever, thresholds for reporting variants depend on the co-
hort and category of results (Table 2).
Genomic analyses
NGS-NBS analysis
This type of analysis is carried out for both cohorts.
Given the large number of possible genomic findings
and the low a priori likelihood that individuals in the
well-child cohort would be affected with any given rare
genetic disorder, we chose to strike a balance between
the sensitivity and the specificity of the analysis. This
balance enables detection of individuals at high risk for a
treatable genetic condition without overwhelming clini-
cians and participants with large numbers of variants of
uncertain significance. Thus, in the NGS-NBS panel,
only variants determined to be known pathogenic or
likely pathogenic and consistent with the expected inher-
itance pattern of the suspected condition are disclosed.
Indication-based analysis
In the diagnosed cohort (children with conditions previ-
ously identified by NBS), we perform an indication-based
analysis that evaluates variants in genes within a specific
(See figure on previous page.)
Fig. 1 Study design workflow. Three phases of the NC NEXUS study workflow. During phase 1, interested parents agree to learn more about the
study and are asked to complete the time 1 pre-decision questionnaire and the time 2 post-decision assessment. Parents use the decision aid to
learn about the study and NGS-NBS for their child and complete informed consent procedures at a clinic study visit if they decide to participate.
During phase 2, samples are obtained after consent is given at study visit 1. Randomization status and NGS-NBS results are returned to parents at
their second study visit. During phase 3, parents in the decision arm decide via a second part of the decision aid whether to consent to and
receive any additional information by phone (for carrier status results) or at a third study visit. Parents randomized to the decision arm also complete a
time 2A post-additional information decision assessment. Both the decision arm and the control arm complete a short-term follow-up assessment and
a long-term follow-up assessment. NBS newborn screening, NGS next-generation sequencing
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Fig. 2 SPIRIT figure. Schedule of enrolment, interventions, and assessments. AI additional information, NBS newborn screening, NGS
next-generation sequencing
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diagnostic list constructed to interrogate all known genes
that could be related to a patient’s phenotype. In the
setting of a diagnostic evaluation, all variants in genes that
could be related to the phenotype are prioritized computa-
tionally and analyzed. Because these children have already
been diagnosed with a rare genetic disorder, variants
deemed to be pathogenic, likely pathogenic, or a variant of
uncertain significance are returned, according to accepted
practice guidelines developed by the American College of
Medical Genetics and Genomics.
Intervention and control conditions
After their NGS-NBS findings are ready to be disclosed,
parents of children in both cohorts are randomized to
one of two study arms: the decision arm or the control
arm (Table 2). Parents assigned to the control arm are
not eligible to request additional findings from their
infant’s or child’s sequencing. Parents assigned to the
decision arm are educated about the scope of additional
findings, as described in phase 2 below, and can request
any or all of the three categories.
Table 1 Inclusion and exclusion criteria
Both cohorts Well-child cohort Diagnosed cohort
Inclusion criteria Parents (couple) or mothers:
• At least 18 years old
• For mothers who are married or
in a marriage-like relationship,
their partners must also consent
to participate. Mothers who are
not married or in a marriage-like
relationship will be able to
participate individually
• Must be able to provide informed
consent for their child and for
themselves
• Must be fluent in English or
Spanish
Parents (couple) or mothers:
• Pregnant with an intrauterine pregnancy
of 18 weeks or longer
• Have been identified by medical
personnel in the obstetric clinic as
eligible candidates.
Newborns:
• Have no pending or positive prenatal
diagnostic test results for congenital
malformations or chromosomal
abnormalities
• Have no complications at the time of
birth or unexpected medical problems;
however, depending on their clinical
course, a sample may be obtained
from infants whose parents have
previously consented to the study
once they have stabilized and been
discharged from the neonatal intensive
care unit, if the parents agree.
Infants and children from 0 to 5 years who
are medically stable and
• Diagnosed with a known or suspected
monogenic disorder, such as:
- Phenylketonuria
- Medium chain acyl-CoA-dehydrogenase
deficiency (MCADD)
- Cystic fibrosis or CFTR-related metabolic
syndrome
- Congenital hearing loss
- Other rare disorders such as primary
ciliary dyskinesia or mucopolysaccharidosis
OR
• Had a positive newborn screen but
follow-up testing was non-confirmatory
(false positive)
Exclusion criteria Parents (couple) and mothers:
• Younger than 18 years old
• Unwilling to complete study procedures
• Have cognitive or other impairments that preclude them from giving informed consent
• Disagree about their child’s participation
• Transfer their prenatal care to another institution
• Are not fluent in English or Spanish
Newborns and children:
• Do not meet the diagnostic criteria as above
• Medically unstable
• Medical care transferred to another institution
Table 2 Categories of results that are returned to the two cohorts of the NC NEXUS study
Categories of results Well-child cohort Diagnosed cohort
NGS-NBS results Only pathogenic variants Only pathogenic variants
Diagnostic results Not applicable Results of indication-based analysis for diagnosed conditions:
phenylketonuria, MCADD, cystic fibrosis, hearing loss,
lysosomal storage diseases, adrenoleukodystrophy, primary
ciliary dyskinesia
Pathogenic, likely pathogenic, and variants of unknown
significance reported
Categories of information that parents randomized to the decision arm are eligible to request:
Childhood-onset non-medically
actionable results
Pathogenic and likely pathogenic variants
reported
Pathogenic and likely pathogenic variants reported
Adult-onset medically actionable
results
Pathogenic and likely pathogenic variants
reported
Pathogenic and likely pathogenic variants reported
Carrier results Pathogenic and likely pathogenic variants
reported
Pathogenic and likely pathogenic variants reported
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Randomization and concealment
Parents are randomized in a 2:1 allocation ratio to the
decision arm or to the control arm, respectively. Comput-
erized randomization uses permuted block randomization
with blocks of randomly varying size. Participants are
stratified for block randomization based on three parame-
ters: study cohort (diagnosed or well-child), language pref-
erence (English or Spanish), and the relationship status of
the parent(s) giving consent (single mother or couple).
Random assignments are concealed electronically using
an automated computer tracking system that does not re-
veal assignments until the time of disclosure. The genetic
counselor who schedules the disclosure visit, who does
not collect questionnaire data from participants, logs into
the system to initiate a participant’s random assignment.
Parents in the decision arm are instructed to complete the
second decision aid prior to their visit and are scheduled
far enough in advance to give them time to do so. Once
participants are scheduled, study staff who manage data
collection and participant communication receive an auto-
mated email alert that prompts them to send a customized
email message to participants. This email includes infor-
mation and materials relevant to the participant’s assigned
condition and a reminder about the date and time of the
disclosure visit.
Decision aid
To help parents make informed decisions about whether to
accept genomic sequencing for their child and about their
preferences for additional information, we developed a
web-based decision aid grounded in principles of informed
decision-making. The content and design of the decision
aid were shaped by insights learned from the NC NEXUS
steering committee, including the extensive clinical experi-
ence of several members, user testing, parent interviews, a
discrete choice experiment, and standards suggested for
decision aids [26–29]. Adopting a user-centered design ap-
proach enabled us to create educational materials that are
accessible and relevant to parents, without sacrificing scien-
tific accuracy [20]. The multimedia interface allows parents
to go at their own pace, repeating and reviewing informa-
tion as needed. Plain-language text, graphics, and audio
narration are used throughout to convey challenging
concepts. The content was organized into three broad
sections: education, deliberation, and decisions. Much of
the education sections focused on defining terms and
explaining what decisions we would ask parents to make.
This included describing the NC NEXUS study procedures,
providing background on NBS and genomic sequencing,
and explaining the kind of results associated with the
NGS-NBS panel and, for parents in the decision arm, the
additional variant analysis. The deliberation portions of the
decision aid were a set of interactive tasks designed to
engage parents in the decision-making process and to
encourage critical thinking about how participating in the
study and learning sequencing results fits with what is most
important to them. In the last section, parents indicate
what they intend to do and are provided with tailored next
steps based on those intentions. The decision aid was
tailored to match parents’ study cohort (well-child or
diagnosed), language preference (English or Spanish), and
relationship status (single or married).
Trial procedures
Phase 1: Education and initial interest in NGS-NBS
After joining the study, each parent in both cohorts is
sent a personalized link to the time 1 (pre-decision base-
line) questionnaire, which is delivered through Qualtrics
(Provo, UT, USA) and optimized for use on mobile
phones, tablets, and computers. The information that
associates these links with personal data is maintained in
a secure database. If parents do not complete the time 1
questionnaire within 1 week of receiving the link, study
staff responsible for communicating with participants
implement a set schedule of email and phone reminders
to encourage parents to complete the questionnaires at
their earliest convenience. The time 1 questionnaire
collects the information summarized in the phase 1
(pre-decision phase) section of Table 3.
After both parents complete the questionnaire, each is
sent a link to the decision aid that describes the
NGS-NBS analysis. Parents use the decision aid to indi-
cate their initial interest in NGS-NBS: (1) decline, (2)
accept, or (3) undecided. Parents who choose option 1
complete a time 2 (post-decision) questionnaire and end
their study participation. Parents who choose options 2
or 3 are contacted to schedule a study visit (visit 1) with
a certified genetic counselor to begin the post-decision
phase (phase 2).
Phase 2: NGS-NBS decision and consent at visit 1,
randomization, and disclosure of NGS-NBS results at visit 2
Parents who selected options 2 or 3 in the decision aid
meet with a certified genetic counselor at visit 1. The
counselor provides additional information about gen-
omic sequencing, the risks and benefits of testing, and
the types of results that can be expected depending upon
the cohort. Depending on the parents’ decision about
NGS-NBS, the genetic counselor obtains signed parental
informed consent for genomic sequencing and the
disclosure of NGS-NBS results to all participants and,
for those in the diagnosed cohort, the results of the
indication-based analysis. Duplicate cheek swab samples
are collected from the children in the diagnosed cohort.
Samples from the well-child cohort are obtained after
the baby’s birth. After the completion of visit 1, each
parent is emailed a link to the time 2 (post-decision)
questionnaire (Table 3). Parents who are unresponsive to
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repeated efforts to schedule visit 1 are sent a letter
asking if they still wish to have NGS-NBS or have
changed their minds. They are also asked if they would
be willing to complete the second questionnaire to en-
able intent-to-treat analyses.
Once NGS-NBS results are ready, participants are
scheduled for a disclosure visit (visit 2), and they are
randomized to the decision arm or the control arm prior
to visit 2. Parents randomized to the decision arm are
emailed a link allowing them to access the second
decision aid that describes the three categories of
additional information that they are eligible to request
from their infant’s or child’s sequencing. They complete
a values-clarification exercise about this decision and
report their intentions to learn any, all, or none of the
categories of additional information.
During visit 2, all parents learn the results from their
infant’s or child’s NGS-NBS (i.e., findings associated with
medically actionable conditions of childhood onset). The
parents of children in the diagnosed cohort also learn the
results of their child’s indication-based analysis. All dis-
closed variants are confirmed by Sanger sequencing in the
clinical laboratory at UNC Hospitals, which is approved
by the Clinical Laboratory Improvement Amendments
program, and clinical reports are generated. Reports are
approved by a board-certified molecular geneticist or
pathologist, and they are eligible to be included in the
electronic health record at the parents’ discretion.
For those in the decision arm, the clinicians then dis-
cuss the additional categories of information parents can
request and ask them to make their decision at that visit.
Parents may request results from some, all, or none of
the three categories of additional information (Table 2).
Immediately after visit 2, parents in the decision arm are
emailed their personal link to complete an online
post-decision questionnaire about their decision about
whether to learn additional information (time 2A ques-
tionnaire). This questionnaire is completed by decision
arm parents only; it documents their experiences and re-
sponses to learning about and making a decision about
additional information.
Because there are multiple steps in this study, we
anticipate that parents may become unavailable,
change their minds about participation, or discontinue
participation. If one parent becomes unavailable after
visit 1 (e.g., moves to another state), the remaining
parent is able to participate as an individual. If we are
unable to schedule visit 1, parents are encouraged to
Table 3 Timing and measures
Measure Citation Scale
information
Time 1
(pre-decision
baseline,
phase 1)
Time 2
(post-decision,
phase 1 or 2a)
Time 2A
(post-additional
information decision,b
phase 2)
Time 3
(short-term
follow-up)
Time 4
(long-term
follow-up)
Sociodemographic variables X
Health literacy [32] 1 item
Likert scale
X
Personal and family history of
genetic testing
5 items
Yes/no
X
Knowledge of genomic
sequencing
[38] 19 items
True/ false
X X X
Understanding NC NEXUS 5 items
True/false
X
General depression and anxiety [43] 14 items
Likert scales
X X X
Decisional conflict [44] 16 items
Likert scale
X X
Decision regret [45] 5 items
Likert scale
X X
Decision regret for additional
informationc
Adapted
from [45]
6 items
Likert scale
X X
Dyadic decision-making
conflict
9 items
Likert scale
X X
Test-related distress [46] 17 items
Likert scale
X X
aThe time 2 questionnaire is administered in phase 1 for participants who decline NGS-NBS in the decision aid and in phase 2 for those who indicate interest in
NGS-NBS in the decision aid by selecting accept or undecided
bThis questionnaire is completed by decision arm participants after they decide to learn all, some, or none of the three categories of additional information
c Relevant to decision arm participants only
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complete the post-decision questionnaire as described
above.
Phase 3: Disclosure of the results of additional information
(decision arm only) and follow-up questionnaire (all
parents)
During phase 3, parents in the decision arm who have
requested results from the carrier status category can
learn these results by telephone. If they have requested
information from either or both of the other categories
(childhood-onset conditions with low or no medical
actionability or adult-onset conditions with high medical
actionability), they are scheduled for a third in-person
study visit (visit 3) for disclosure by a medical geneticist
and genetic counselor. All parents, regardless of their
randomly assigned study group, complete two additional
follow-up questionnaires after visit 2: the time 3 ques-
tionnaire, which collects data for a short-term follow-up
within 2 weeks [30, 31] of the return of results (visit 2
for those in the control arm and visit 3 for those in the
decision arm), and the time 4 questionnaire, which
collects data for a long-term follow-up 3 months after
the participants’ final visit (Table 3).
Data monitoring
Study data flows are coordinated by workflow manage-
ment software that directs interaction among different
software systems that are isolated to maintain the secur-
ity of different types of study information. Participant
demographic data and consent documents are collected
and managed using the REDCap [31] electronic data
capture tools hosted at UNC. Survey data are obtained
using direct entry by parent participants. Participants are
provided individualized web links using a secondary
coded identifier, so that the primary coded identifier is
protected. Questionnaires are provided using the Qual-
trics survey tool. Bioinformatics processing of sequence
data are performed on systems isolated from the RED-
Cap instance and use only the coded participant identi-
fiers. The project workflow management software
communicates with the decision aid software, the Qual-
trics survey tool, and the bioinformatics processing soft-
ware using defined interfaces over transport layer
security.
Measures
Self-report measures are administered through online
questionnaires (Table 3). When participating as a couple,
each parent completes the questionnaires independently.
We emphasize that we use measures that are valid, reli-
able, brief, and appropriate for a diverse population. The
measures assess variables needed to describe the sample
potential confounds that may need to be included as
covariates during analyses, and self-reported primary and
secondary outcome variables. Participants complete up to
five assessments. All participants complete a time 1
(pre-decision baseline) questionnaire, which is sent elec-
tronically before they complete the NGS-NBS decision
aid, and a time 2 (post-decision) questionnaire. Partici-
pants who decline NGS-NBS in the first decision aid
complete the time 2 questionnaire after indicating their
choice in the decision aid and then their participation
ends, whereas those who indicate accept or undecided in
the decision aid enter phase 2 and complete the time 2
questionnaire after visit 1, when they make their final
decision about NGS-NBS. Participants in the decision
arm also complete a time 2A (post-additional information
decision) questionnaire after visit 2. In phase 3, all partici-
pants complete two more questionnaires. In the control
arm, participants complete the time 3 questionnaire
(short-term follow-up) after visit 2. In the decision arm,
the time 3 questionnaire is completed after visit 3. In both
arms, a final questionnaire (long-term follow-up) is com-
pleted 4 months after their final visit.
Sociodemographic variables are collected in the time 1
questionnaire. Both parents report individual-level vari-
ables, which include age, gender, ethnicity (Hispanic or
non-Hispanic), race, marital status, education, employ-
ment status, and health insurance status. Mothers report
relationship-level demographic characteristics, which
include family income, length of relationship, and parity.
Both parents’ health literacy is also assessed at time 1
with the Single Item Literacy Screener [32].
Measures assessing parents’ reactions to the study and to
decision-making are summarized in Table 3. These mea-
sures include the self-reported primary outcome of decision
regret and secondary outcomes including test-related dis-
tress, decisional conflict, understanding of NC NEXUS
study features, general depression, and anxiety.
Planned analyses
Analyses will begin with descriptive statistics for all
study variables. We will evaluate the distribution of
continuous variables and, if necessary, apply normalizing
or variance stabilizing transformations before conduct-
ing further analyses. We will use current methods for
evaluating patterns of missing data and for imputing
missing values, if appropriate. Analyses will evaluate the
success of randomization (i.e., to ensure that participants
in the study arms do not differ on demographic variables
or the child’s medical variables) and include any factors
shown to differ as covariates in multivariate models. We
will also use an intent-to-treat approach to compare
groups. The analytic approach for analyses will be deter-
mined by the nature of the outcome (discrete or con-
tinuous), need to include covariates, and the research
question being addressed. Analyses will be performed by
an experienced biostatistician and will apply currently
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recommended approaches used in randomized con-
trolled trials and subgroup analyses [33]. For example,
one analysis will focus on one of the three primary
participant-reported outcomes: mothers’ decision regret
assessed at the time 3 short-term follow-up. We will
conduct an analysis of covariance that includes a variable
identifying the assigned study arm (decision or control)
and any necessary covariates, selected from demographic
or medical variables found to differ across the two study
arms at the time 1 pre-decision baseline assessment (if
any such imbalance is detected) as well as demographic
or medical variables associated with the outcome. If
learning about and making a decision about additional
information from a child’s sequencing increases regret at
having decided to join the study, then we would expect
this outcome to be elevated in the decision arm. We will
also explore the cohort/study arm interaction to evaluate
whether the effects of assignment to the decision arm
differ across cohorts. Statistical adjustments for multiple
comparisons will not be used, given the nature of our
planned analyses.
Sample size
NC NEXUS will seek to enroll 200 children into the
well-child cohort and into the diagnosed cohort (400
children total), along with their parent or parents, with
enrollment indicated by consent to participate in phase 1
of the study. Power analyses were conducted to evaluate
statistical power for evaluating the effects of randomizing
parents to make the decision (or not) to request additional
information from their child’s sequencing. Using PASS
Version 11 [34], we estimated the statistical power for
detecting the difference in mother’s decision regret. Given
Cohen’s d = 0.3, which is an effect size considered to be
clinically meaningful in patient-reported outcome data
[35], the study has a statistical power of 81% to detect the
difference under type I error alpha = 0.05 and sample size
n = 400. It also has sufficient power to explore a multiple
regression model predicting mothers’ decisional regret with
two covariates of substantive interest (cohort and race/eth-
nicity) and 10 covariates in the model (e.g., demographics)
that account for 20% of the variance in scores. We as-
sumed the sample will be split equally across racial/ethnic
groups under complete randomization, which is consistent
with the distribution in our study population. If study
group and race/ethnicity account for 2% or more of the
variance after controlling for the other variables, we will
have statistical power of at least 82% under alpha = 0.05,
indicating acceptable power for comparisons by study
group and race/ethnicity.
Potential harms
The risks of study participation can be divided between
those generic risks inherent to genetic research with
human subjects and risks that are unique to the NC
NEXUS project. Although the potential harms of genetic
testing in the newborn period have been hypothesized
(vulnerable child syndrome, genetic discrimination, paren-
tal bonding, among others), few data are available to docu-
ment whether these harms occur and their duration and
magnitude [36, 37]; however, the use of genome-scale
sequencing heightens the need to collect these data. NC
NEXUS was specifically designed to gather empirical
evidence regarding potential benefits and harms of the use
of NGS in NBS. Although longitudinal studies are needed
to characterize them fully, this study seeks to identify
potential risks associated with parental responses to learn-
ing genetic information about their child. To minimize
the psychological risks, the disclosure of positive results is
done in conjunction with genetic counseling, and referrals
to specialists are made as needed. In addition, the clinical
team that has contact with study participants is trained to
recognize and probe indicators of possible distress (e.g.,
participants’ description or display of distress-related
symptoms). A measure of participant distress (depressive
symptoms and anxiety) is included in questionnaires that
participants complete before and after the results are
disclosed to establish baseline levels and examine changes
in distress over time [38]. Finally, the decision aid was
designed to help families understand the risks and benefits
of study participation and to make an informed decision
based on their values and preferences. This information is
expanded and personalized during the in-person informed
consent visit. As with all research studies, a study partici-
pant may discontinue their involvement at any time.
All clinical information is kept confidential, and only
accessed by those directly involved in the research. The
digital file containing the linked participant names, UNC
medical record numbers and unique study identifiers is
stored in a password-protected REDCap database man-
aged by the North Carolina Translational and Clinical
Sciences Institute. All identifiers (name, date of birth,
etc.) are removed from the saliva samples prior to being
sent for DNA extraction.
Ethical and regulatory considerations
The NC NEXUS study has had regulatory oversight by
the Food and Drug Administration (FDA) since the
beginning of the study. Based on concerns about the
potential harms of returning predictive genomic results
to healthy newborns, the FDA declared NC NEXUS a
significant risk device study (investigational device ex-
emption G150258). The study is approved by the
Biomedical IRB of UNC.
The data in this study is reviewed regularly by an inde-
pendent data monitor as required by investigational de-
vice exemption G150258, in accordance with established
good clinical practices of the International Conference
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on Harmonization (E6 5.1.1, 5.2, 5.18.1) and 21 CFR
812.40 [39], and a clinical monitoring plan developed
specifically for the NC NEXUS project by the study data
monitor. The role of the data monitor is to review study
documentation, regulatory files, and informed consent
to ensure the quality and integrity of the data collected
and adherence to good clinical practices. An important
focus of the data monitoring is to ensure appropriate
informed consent has been obtained from the research
participants. Areas of deficiencies and timelines for
resolution will be documented and agreed upon by the
study team and the monitor.
Following the FDA Guidelines for the Establishment
and Operation of Clinical Trial Data Monitoring
Committees Section 2 [40], a formal data monitoring
committee is not needed for trials that are not “intended
to prolong life or reduce risk of a major adverse health
outcome such as a cardiovascular event or recurrence or
cancer, … unless the trial population is at elevated risk
of more severe outcomes.”
Discussion
The NC NEXUS study is led by an interdisciplinary team
and is examining the technical, clinical, and ethical issues
associated with utilizing genome-scale sequencing tech-
nology to screen newborns. The benefits of genome-scale
diagnostic testing have largely been demonstrated; how-
ever, the use of genomic sequencing as a public health
screening tool merits systematic study. Expanding the
amount and types of information parents can learn about
their newborns will fundamentally alter the limited role
parents have traditionally played in this setting. NC
NEXUS will study not only how parents make decisions
about NBS that incorporates NGS, but it will also advance
knowledge by using a rigorous randomized controlled trial
design to investigate the effects of being given, versus not
being given, a choice to learn additional findings from a
child’s sequencing.
Though relevant to the ethical application of NGS
technologies to genetic screening in any population, the
issues stemming from the pediatric setting are particu-
larly controversial because policy recommendations have
generally concluded that asymptomatic testing of minors
should be done only when timely identification is needed
to prevent harm and directly benefit the child. In
addition, factors that influence the decision to learn
genetic information has largely focused on adults decid-
ing about their own genome; much less is known about
surrogate decision-making, as occurs with NBS.
The potential to expand significantly the number and
types of conditions identified by NBS underscores the
need for studies of the specificity and sensitivity of NGS
for detecting disorders with a genetic etiology in asymp-
tomatic individuals. There is a profound lack of data
about the predictive value of genomic sequencing in a
public health screening setting, and the difficulty of
interpreting the pathogenicity of novel and rare genetic
variants is compounded by the lack of clinically relevant
phenotypes for comparative inference. Enrollment of
cohorts with known disorders identified through recent
routine NBS will allow us to assess, in a blinded fashion,
the sensitivity of our NGS-NBS panel and workflow for
three types of conditions most commonly detected
through traditional NBS methods.
In addition, determining those genes for which identi-
fied pathogenic variants would be medically actionable
as well as those that, while not providing direct medical
benefit to the child, could benefit the family, is a signifi-
cant focus of this study. One novelty of the NC NEXUS
study is in its examination of how parents in real-world
settings make decisions about a wide range of genetic
information and the subsequent impact of these deci-
sions. By identifying and disclosing genetic information
that extends beyond the original purpose of NBS, the
study may help redefine the disclosure criteria in the
newborn period.
The complexity and breadth of information obtainable
through genome-scale sequencing could disrupt the
process by which NBS is currently delivered, which is a
setting in which parents are typically not well informed
about testing and are not asked to provide consent. If
parents are expected to make decisions about learning
information that may not meet current thresholds of
actionability, they will need specific guidance about how
to decide which information they would prefer to learn
and which they would not. Integral to this process is the
elicitation and incorporation of their beliefs and values
into their personal assessments of the benefits and risks
of learning various types of information. Existing educa-
tional efforts are inadequate to achieve this goal and
new, validated tools will need to be developed. The NC
NEXUS electronic decision aid was designed with this
goal in mind. It combines the theory and principles of
informed decision-making to teach parents about the
testing and the kinds of results they might expect. It also
helps them to predict their reactions to learning this
information and to identify their options.
Increasing public awareness about the potential uses of
genetic information has driven the expectation that genomic
testing modalities will play a major role in diagnosing, treat-
ing, and preventing disease in the future. For example, com-
mercial laboratories currently market direct-to-consumer
genomic sequencing of newborns [41, 42], heightening
concerns about the clinical validity and long-term impact of
returning different types of genetic information to par-
ents of newborns. These concerns, coupled with the
likelihood that genomic screening technology will even-
tually be adopted into neonatal public health screening,
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emphasize the need for a practical and ethical infra-
structure, including validated decision-support mate-
rials and an evidence-based process, by which to apply
genomic sequencing to NBS for the tangible benefit of
parents and children.
Genomic sequencing offers great promise for detecting
causative mutations in actionable early-onset conditions
that are not currently detectable by traditional NBS
methods; however, more research is needed to understand
the inherent ethical, social, and public health dilemmas. A
broader understanding of several aspects is needed to
facilitate incorporation of NGS into newborn public health
screening and inform development of important future
NBS policy guidelines. These include how parents under-
stand NGS-NBS, the decisions that they make, the role of
a decision aid and the supporting clinical interactions in
influencing parents’ decisions, and the ramifications of
disclosure for family adaptation. We are optimistic that
the NC NEXUS study will provide highly relevant infor-
mation to address the central challenges facing the clinical
implementation of genome-scale analysis in children and
contribute to the establishment of best practices for NBS.
Trial status
Patient recruitment began on 14 June 2016 under Version
1 of IRB protocol 13–2409 and will end on 1 May 2018.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 255 kb)
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